Humacyte, Inc. (HUMA) stock

HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 2/30

$0.59+0.00 (+0.29%)

Close on Nov 11, 2026Market cap $164.37MP/E –Yield –

Humacyte gross margin

Gross margin is gross profit as a percentage of revenue.

Humacyte's gross margin for the twelve months ending Sep 30, 2026 was -475.1%. For fiscal 2025 it was -376.1%.

Annual gross margin

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	-376.1%	–

Quarterly gross margin

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q3 FY2026	Sep 30, 2026	-39.0%	−104.5
Q2 FY2026	Jun 30, 2026	-203.2%	−232.4
Q1 FY2026	Mar 31, 2026	-311.7%	−383.3
Q4 FY2025	Dec 31, 2025	-1844.8%	–
Q3 FY2025	Sep 30, 2025	65.5%	–
Q2 FY2025	Jun 30, 2025	29.2%	–
Q1 FY2025	Mar 31, 2025	71.6%	–

Where these numbers come from

Parsed from the XBRL in Humacyte's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Nov 15, 2021
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is HUMA.

Compare: HUMA vs DYAI · HUMA vs PROK · HUMA vs PRME · HUMA vs PLUR · HUMA vs ATRA

Revenue growth52.5% · median -1.9%

Gross margin-475.1% · median 34.1%

Operating margin-4602.9% · median -1342.3%

Net margin-3955.1% · median -1156.2%

Company	Revenue	Growth
ATRA	$3.97M	-97.4%
DYAI	$3.80M	-8.0%
HUMA	$2.40M	+52.5%
PLUR	$1.46M	+10.0%
PROK	$775.00K	+4.2%
PRME	–	–

Company

Next earnings (est.): Mar 18, 2027, before open
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 184
Held by institutions: 26.4%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 1818382

Advertisement
300 × 250

See a number that looks wrong?